Prostatype Genomics AB
STO:PROGEN

Watchlist Manager

Prostatype Genomics AB

STO:PROGEN

Watchlist

Discount Rate

Price: 0.018 SEK -5.26% Market Closed

Market Cap: 17.8m SEK

Have any thoughts about
Prostatype Genomics AB?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	Abbvie Inc NYSE:ABBV	Biotechnology
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Realty Income Corp NYSE:O	Real Estate
US	Walt Disney Co NYSE:DIS	Media
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 0.018 SEK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

PROGEN Alert

Prostatype Genomics AB

0.018

-0.001 (-5.26%)

52 Week Range	0.0125 0.2252
Price Target

We'll email you a reminder when the closing price reaches SEK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	Abbvie Inc NYSE:ABBV	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Realty Income Corp NYSE:O	US
	Walt Disney Co NYSE:DIS	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Prostatype Genomics AB

What unique competitive advantages
does Prostatype Genomics AB hold over its rivals?

What risks and challenges
does Prostatype Genomics AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Prostatype Genomics AB.

What unique competitive advantages
does Prostatype Genomics AB hold over its rivals?

What risks and challenges
does Prostatype Genomics AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Prostatype Genomics AB.

Provide P/S
for Prostatype Genomics AB.

Provide P/E
for Prostatype Genomics AB.

Provide P/OCF
for Prostatype Genomics AB.

Provide P/FCFE
for Prostatype Genomics AB.

Provide P/B
for Prostatype Genomics AB.

Provide EV/S
for Prostatype Genomics AB.

Provide EV/GP
for Prostatype Genomics AB.

Provide EV/EBITDA
for Prostatype Genomics AB.

Provide EV/EBIT
for Prostatype Genomics AB.

Provide EV/OCF
for Prostatype Genomics AB.

Provide EV/FCFF
for Prostatype Genomics AB.

Provide EV/IC
for Prostatype Genomics AB.

What are the Revenue projections
for Prostatype Genomics AB?

How accurate were the past Revenue estimates
for Prostatype Genomics AB?

What are the Net Income projections
for Prostatype Genomics AB?

How accurate were the past Net Income estimates
for Prostatype Genomics AB?

What are the EPS projections
for Prostatype Genomics AB?

How accurate were the past EPS estimates
for Prostatype Genomics AB?

What are the EBIT projections
for Prostatype Genomics AB?

How accurate were the past EBIT estimates
for Prostatype Genomics AB?

Compare the revenue forecasts
for Prostatype Genomics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Prostatype Genomics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Prostatype Genomics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Prostatype Genomics AB compared to its peers.

Compare the P/E ratios
of Prostatype Genomics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Prostatype Genomics AB with its peers.

Analyze the financial leverage
of Prostatype Genomics AB compared to its main competitors.

Show all profitability ratios
for Prostatype Genomics AB.

Provide ROE
for Prostatype Genomics AB.

Provide ROA
for Prostatype Genomics AB.

Provide ROIC
for Prostatype Genomics AB.

Provide ROCE
for Prostatype Genomics AB.

Provide Gross Margin
for Prostatype Genomics AB.

Provide Operating Margin
for Prostatype Genomics AB.

Provide Net Margin
for Prostatype Genomics AB.

Provide FCF Margin
for Prostatype Genomics AB.

Show all solvency ratios
for Prostatype Genomics AB.

Provide D/E Ratio
for Prostatype Genomics AB.

Provide D/A Ratio
for Prostatype Genomics AB.

Provide Interest Coverage Ratio
for Prostatype Genomics AB.

Provide Altman Z-Score Ratio
for Prostatype Genomics AB.

Provide Quick Ratio
for Prostatype Genomics AB.

Provide Current Ratio
for Prostatype Genomics AB.

Provide Cash Ratio
for Prostatype Genomics AB.

What is the historical Revenue growth
over the last 5 years for Prostatype Genomics AB?

What is the historical Net Income growth
over the last 5 years for Prostatype Genomics AB?

What is the current Free Cash Flow
of Prostatype Genomics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Prostatype Genomics AB.

EV/OCF
Enterprise Value to OCF

-0.5

Current

-9.9

Median

6.6

Industry

Higher than median

Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF

-0.5

Enterprise Value

16m SEK

Operating Cash Flow

-33.1m SEK

All Countries

Forward Multiples

			Market Cap	EV/OCF
SE	P	Prostatype Genomics AB STO:PROGEN	17.8m SEK	-0.5
US		Abbvie Inc NYSE:ABBV	341.9B USD	20.8
US		Amgen Inc NASDAQ:AMGN	180.5B USD	35.4
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	129B USD	29.9
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	123.6B USD	-125.1
US		Gilead Sciences Inc NASDAQ:GILD	104.5B USD	16.5
US	E	Epizyme Inc F:EPE	94.1B EUR	-504
AU		CSL Ltd ASX:CSL	142.3B AUD	38.6
US	S	Seagen Inc F:SGT	39.3B EUR	-79
US	P	Palatin Technologies Inc LSE:0KF3	38.5B USD	-1 111.2
US		Alnylam Pharmaceuticals Inc NASDAQ:ALNY	35.4B USD	90.7


SE	P	Prostatype Genomics AB STO:PROGEN	Average EV/OCF: 38.6 Negative Multiple: -0.5
US		Abbvie Inc NYSE:ABBV	20.8
US		Amgen Inc NASDAQ:AMGN	35.4
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	29.9
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	Negative Multiple: -125.1
US		Gilead Sciences Inc NASDAQ:GILD	16.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -504
AU		CSL Ltd ASX:CSL	38.6
US	S	Seagen Inc F:SGT	Negative Multiple: -79
US	P	Palatin Technologies Inc LSE:0KF3	Negative Multiple: -1 111.2
US		Alnylam Pharmaceuticals Inc NASDAQ:ALNY	90.7

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/OCF

N/A

2-Years Forward

EV/OCF

N/A

3-Years Forward

EV/OCF

N/A

Prostatype Genomics AB
STO:PROGEN

EV/OCF
Enterprise Value to OCF

EV/OCF Forward Multiples

See Also

Company

Help

Tools

Stocks

Prostatype Genomics AB STO:PROGEN

EV/OCF Enterprise Value to OCF

EV/OCF Forward Multiples

See Also

Company

Help

Tools

Stocks

Prostatype Genomics AB
STO:PROGEN

EV/OCF
Enterprise Value to OCF